QQQ   414.73 (-2.05%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   146.98 (-1.97%)
NVDA   769.00 (-9.18%)
AMD   146.18 (-5.74%)
NIO   3.81 (-4.75%)
BABA   69.05 (+0.25%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   106.48 (-4.87%)
GE   148.44 (-2.94%)
CGC   8.05 (+2.81%)
DIS   112.31 (-0.11%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.97 (+1.22%)
QQQ   414.73 (-2.05%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   146.98 (-1.97%)
NVDA   769.00 (-9.18%)
AMD   146.18 (-5.74%)
NIO   3.81 (-4.75%)
BABA   69.05 (+0.25%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   106.48 (-4.87%)
GE   148.44 (-2.94%)
CGC   8.05 (+2.81%)
DIS   112.31 (-0.11%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.97 (+1.22%)
QQQ   414.73 (-2.05%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   146.98 (-1.97%)
NVDA   769.00 (-9.18%)
AMD   146.18 (-5.74%)
NIO   3.81 (-4.75%)
BABA   69.05 (+0.25%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   106.48 (-4.87%)
GE   148.44 (-2.94%)
CGC   8.05 (+2.81%)
DIS   112.31 (-0.11%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.97 (+1.22%)
QQQ   414.73 (-2.05%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   146.98 (-1.97%)
NVDA   769.00 (-9.18%)
AMD   146.18 (-5.74%)
NIO   3.81 (-4.75%)
BABA   69.05 (+0.25%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   106.48 (-4.87%)
GE   148.44 (-2.94%)
CGC   8.05 (+2.81%)
DIS   112.31 (-0.11%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.97 (+1.22%)
Free Trial
ASX:NEU

Neuren Pharmaceuticals (NEU) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)
Free NEU Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
57,935 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
NEU stock logo

About Neuren Pharmaceuticals Stock (ASX:NEU)

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

NEU Stock News Headlines

April 3, 2024 | msn.com
ASX loses 1.3% on back of Wall Street decline, gold price hits new high and the world's richest people are getting richer — as it happened
April 1, 2024 | finance.yahoo.com
Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
April 19, 2024 | Stansberry Research (Ad)
Strange new buyer driving up gold
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
March 26, 2024 | uk.finance.yahoo.com
20 Biggest Health Care Companies in Australia, 2024
March 18, 2024 | fool.com.au
The best ASX shares to invest $500 in right now
March 11, 2024 | fool.com.au
$10k of savings? I'd buy these ASX 200 shares to grow my money
March 3, 2024 | finance.yahoo.com
Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
February 29, 2024 | fool.com.au
What's with the Neuren Pharmaceuticals share price today?
April 19, 2024 | Stansberry Research (Ad)
Strange new buyer driving up gold
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
February 28, 2024 | msn.com
Inflation remains at two-year low, Optus sacks extra 200 staff, Sony terminates 8pc of workforce, ASX finishes flat — as it happened
February 28, 2024 | fool.com.au
Why is this ASX 200 pharmaceuticals stock crashing 15% today?
February 16, 2024 | msn.com
Neuren (NEU) Shares Plunge as Short Seller Targets Partner Acadia
February 15, 2024 | fool.com.au
This ASX 200 healthcare share is diving 13% as short sellers take aim
January 18, 2024 | forbes.com
Stock Market Outlook In 2024
January 15, 2024 | markets.businessinsider.com
Jefferies Keeps Their Buy Rating on Clinuvel Pharmaceuticals Limited (CLVLF)
January 12, 2024 | fool.com.au
3 pharma shares outshining the ASX index today
January 8, 2024 | fool.com.au
The Neuren Pharmaceuticals share price is up 100% in 3 months: Can it keep rising?
January 6, 2024 | fool.com.au
The No. 1 ASX 200 shares of each market sector in 2023
January 4, 2024 | markets.businessinsider.com
Analysts Are Bullish on These Healthcare Stocks: Innovent Biologics (IVBXF), Telix Pharmaceuticals Ltd. (TLPPF)
December 26, 2023 | finance.yahoo.com
An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 44% Undervalued
December 22, 2023 | fool.com.au
Why Boss Energy, Lynas, Neuren, and Ora Banda shares are rising today
December 19, 2023 | au.investing.com
Neuren Pharmaceuticals' shares surge on positive Phase 2 clinical trial results
December 18, 2023 | fool.com.au
Guess which ASX 200 stock was just upgraded and tipped to rise 20%+
December 17, 2023 | fool.com.au
Why is this ASX 200 healthcare stock surging 32% on Monday?
December 13, 2023 | finance.yahoo.com
Australia Shares Rise, Helped by Healthcare Stocks
December 10, 2023 | afr.com
New fund targets companies battered by market doubts
November 6, 2023 | morningstar.com
Neuren Pharmaceuticals Ltd NEU
See More Headlines
Receive NEU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2019
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:NEU
CUSIP
N/A
CIK
N/A
Web
www.neurenpharma.com
Phone
61 3 9092 0480
Fax
N/A
Employees
2,105
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A$1.20
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$157.08 million
Net Margins
67.72%
Pretax Margin
N/A
Return on Equity
127.30%
Return on Assets
85.52%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.78
Quick Ratio
31.54

Sales & Book Value

Annual Sales
$231.94 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
12.46
Book Value
A$1.61 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
129,950,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
1.99
The 10 Best AI Stocks to Own in 2024 Cover
The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Jonathan Charles Pilcher A.C.A.
    ACA, B.Sc., BSc (Hons), F.C.A., CEO, MD & Executive Director
  • Ms. Lauren Frazer C.A.
    CFO & Company Secretary
  • Mr. Lawrence Glass BA (Biology)
    Chief Science Officer
  • Mr. Gerry Zhao
    Vice President of Corporate Development
  • Dr. Liza A. Squires M.D.
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders


NEU Stock Analysis - Frequently Asked Questions

How were Neuren Pharmaceuticals' earnings last quarter?

Neuren Pharmaceuticals Limited (ASX:NEU) released its earnings results on Wednesday, February, 27th. The company reported $0.03 earnings per share (EPS) for the quarter. Neuren Pharmaceuticals had a trailing twelve-month return on equity of 127.30% and a net margin of 67.72%.

What other stocks do shareholders of Neuren Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuren Pharmaceuticals investors own include Macquarie Group (MQG), Magellan Financial Group (MFG), Medlab Clinical (MDC), FBR (FBR), Embark Early Education (EVO), Dacian Gold (DCN), Constellation Technologies (CT1), Afterpay (APT) and Alkane Resources (ALK).

This page (ASX:NEU) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
My biggest AI fear
Paradigm Press